BR112023022331A2 - Métodos de fabricação de um composto de heparina de alto peso molecular - Google Patents

Métodos de fabricação de um composto de heparina de alto peso molecular

Info

Publication number
BR112023022331A2
BR112023022331A2 BR112023022331A BR112023022331A BR112023022331A2 BR 112023022331 A2 BR112023022331 A2 BR 112023022331A2 BR 112023022331 A BR112023022331 A BR 112023022331A BR 112023022331 A BR112023022331 A BR 112023022331A BR 112023022331 A2 BR112023022331 A2 BR 112023022331A2
Authority
BR
Brazil
Prior art keywords
molecular weight
heparin
high molecular
manufacturing
kda
Prior art date
Application number
BR112023022331A
Other languages
English (en)
Inventor
Jessica Pax
Li Fu
Zhenyu Wang
Original Assignee
Nexeos Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexeos Diagnostics Inc filed Critical Nexeos Diagnostics Inc
Publication of BR112023022331A2 publication Critical patent/BR112023022331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Sustainable Development (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

métodos de fabricação de um composto de heparina de alto peso molecular. é descrito um método de fabricação de um composto de heparina de alto peso molecular (hmwh). o método compreende dissolver a heparina para formar uma solução de heparina e fracionar a solução de heparina através de filtração de fluxo tangencial (tff) utilizando uma membrana com um peso molecular de corte (mwco) entre cerca de 8 kda e cerca de 12 kda. a tff produz um retentado compreendendo heparina fracionada com um peso molecular médio ponderado de cerca de 20 kda ou superior, isto é, um composto de heparina de alto peso molecular. uma proporção substancial de cadeias de heparina na heparina fracionada pode ter um peso molecular elevado, por exemplo, 50 % das cadeias de heparina ou mais podem ter um peso molecular de 20 kda ou mais.
BR112023022331A 2021-05-12 2022-05-12 Métodos de fabricação de um composto de heparina de alto peso molecular BR112023022331A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187624P 2021-05-12 2021-05-12
PCT/US2022/029014 WO2022241130A1 (en) 2021-05-12 2022-05-12 Methods of manufacturing a high molecular weight heparin compound

Publications (1)

Publication Number Publication Date
BR112023022331A2 true BR112023022331A2 (pt) 2023-12-26

Family

ID=81927418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022331A BR112023022331A2 (pt) 2021-05-12 2022-05-12 Métodos de fabricação de um composto de heparina de alto peso molecular

Country Status (11)

Country Link
US (2) US11712447B2 (pt)
EP (1) EP4326782A1 (pt)
JP (1) JP2024518174A (pt)
KR (1) KR20240006648A (pt)
CN (1) CN117295772A (pt)
AU (1) AU2022273722A1 (pt)
BR (1) BR112023022331A2 (pt)
CA (1) CA3217273A1 (pt)
IL (1) IL308411A (pt)
MX (1) MX2023013300A (pt)
WO (1) WO2022241130A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35770E (en) * 1978-11-06 1998-04-14 Choay, S.A. Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them
US4446126A (en) 1980-09-30 1984-05-01 Cutter Laboratories, Inc. Antithrombin-heparin complex and method for its production
US4539398A (en) 1982-01-22 1985-09-03 Riker Laboratories, Inc. Affinity fractionation of heparin on immobilized Concanavalin A
IT1290814B1 (it) 1997-03-24 1998-12-11 Istituto Scient Di Chimica E B Glicosaminoglicani aventi elevata attivita' antitrombotica
AU2745700A (en) 1999-02-01 2000-08-18 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
JP2009538386A (ja) * 2006-05-25 2009-11-05 モメンタ ファーマシューティカルズ インコーポレイテッド 低分子量ヘパリン組成物およびその使用
GB0812919D0 (en) * 2008-07-15 2008-08-20 Norwegian University Of Life Sciences Process
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
WO2011097148A2 (en) 2010-02-04 2011-08-11 Parsons Lowell C Use of oral heparin preparations to treat urinary tract diseases and conditions
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013173716A2 (en) 2012-05-18 2013-11-21 University Of Utah Research Foundation Methods for diagnosing and monitoring eosinophilic esophagitis
BR102014027804B1 (pt) 2014-11-07 2020-12-01 Universidade Estadual Paulista Julio De Mesquita Filho processo de desenvolvimento de heparina não fracionada de alto peso molecular, heparina não fracionada de alto peso molecular e usos da mesma
RU2606836C2 (ru) 2015-03-12 2017-01-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Антикоагулянтный, антитромбоцитарный и фибриндеполимеризационный комплекс на основе гепарина, способ его получения и применение
WO2020216981A1 (es) * 2019-04-26 2020-10-29 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de obtención de heparinas de bajo peso molecular por filtración de flujo tangencial
MX2022009732A (es) 2020-02-10 2022-09-09 Univ Utah Res Found Composiciones de heparina de alto peso molecular y metodos para diagnosticar, tratar y monitorear enfermedades inflamatorias mediadas por eosinofilos.

Also Published As

Publication number Publication date
US20230321137A1 (en) 2023-10-12
US20220362283A1 (en) 2022-11-17
MX2023013300A (es) 2023-12-04
KR20240006648A (ko) 2024-01-15
JP2024518174A (ja) 2024-04-25
IL308411A (en) 2024-01-01
CN117295772A (zh) 2023-12-26
EP4326782A1 (en) 2024-02-28
CA3217273A1 (en) 2022-11-17
WO2022241130A1 (en) 2022-11-17
AU2022273722A1 (en) 2023-11-02
US11712447B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
KR101480585B1 (ko) 신규 저분자화 콘드로이틴황산 및 그 용도
BR112023022331A2 (pt) Métodos de fabricação de um composto de heparina de alto peso molecular
BR0007522A (pt) Processo e aparelho para processamento de micelas de óleo vegetal
BR0317533A (pt) Membranas semi-permeáveis de polissulfona "melt spun" e métodos para fabricá-las
BRPI0507724A (pt) processo para a produção de uma membrana integralmente assimétrica, membrana integralmente assimétrica e uso de uma membrana
BRPI0920270A8 (pt) Composições líquidas polimerizáveis do tipo poliuretano, método para produzir vidro orgânico, vidros orgânicos, e, produtos ou itens ópticos manufaturados
RU2012146077A (ru) Удаление побочных продуктов реакции и примесей из карамельного красителя и стабильный при хранении концентрат карамельного красителя
CO2021013320A2 (es) Procedimiento de obtención de heparinas de bajo peso molecular por filtración de flujo tangencial
Korach et al. Plasma exchange in France: epidemiology 2001
BR112022017373A2 (pt) Composições de mudança de cor fotocuráveis e método para formar características sobre uma superfície da membrana usando o mesmo
AR084625A1 (es) Metodo para la preparacion de sulfato de condroitina sodico
BR9914597A (pt) Membranas contendo poliétercetona sulfonada e outro polìmero, processo para produção das mesmas e uso das mesmas
BR112023021750A2 (pt) Métodos de fabricação de composições de aveia e composição de aveia
NI202000046A (es) Métodos para identificar y aislar compuestos bioactivos de extractos de algas
AR118776A1 (es) Procedimiento de obtención de heparinas de bajo peso molecular por filtración de flujo tangencial
JI et al. Effect of the fracture line direction in the sagittal profile on the Gartland type Ⅲ supracondylar humerus fractures in children
Perumbally et al. Mucosal Grading and Its Use in the Management of Chronic Otitis Media-Mucosal Disease
SHANG et al. Effect of Chaihu Jia Longgu Mulitang on Signaling Pathway of PI3K/Akt/GSK3β/β-catenin in Hippocampus Tissue of Rats with Depression
SHEN Comparison of the effects of citric acid and low molecular weight heparin on hemodialysis patients at high risk of bleeding
RU2018136935A (ru) Способ получения кровезаменителя для применения в ветеринарии
CL2021002313A1 (es) Composición de la inulina y procedimiento de purificación de la inulina.
Sun et al. Effect of nocturnal hemodialysis on dialysis complications and tolerability in maintenance hemodialysis patients
Saffour et al. Interest of beta 2-microglubulin determination in chronic hemodialysis patients
LI et al. Influence factors of delayed recovery after right ventricular-extrapulmonary arterial conduit reconstruction
QI et al. Efficacy and safety of nalbuphine in preventing the side effect of pruritus induced by intrathecal morphine after cesarean section